As the company announced on August 14, 2019, AgeX has obtained a USD 2m credit facility from Juvenescence to finance AgeX's operations and advance its product development programmes.
AgeX Therapeutics, Inc. (NYSE American: AGE) is focused on developing and commercializing innovative therapeutics for human aging.
Its PureStem and UniverCyte manufacturing and immunotolerance technologies are designed to work together to generate highly-defined, universal, allogeneic, off-the-shelf pluripotent stem cell-derived young cells of any type for application in a range of diseases with a high unmet medical need.
AgeX has two preclinical cell therapy programs: AGEX-VASC1 (vascular progenitor cells) for tissue ischemia and AGEX-BAT1 (brown fat cells) for Type II diabetes. AgeX's revolutionary longevity platform induced Tissue Regeneration aims to unlock cellular immortality and regenerative capacity to reverse age-related changes within tissues.
AGEX-iTR1547 is an iTR-based formulation in preclinical development. HyStem is AgeX's delivery technology to stably engraft PureStem cell therapies in the body.
AgeX is developing its core product pipeline for use in the clinic to extend human healthspan and is seeking opportunities to establish licensing and collaboration agreements around its broad IP estate and proprietary technology platforms.
Mozart Therapeutics presents MTX-101 clinical and preclinical data at EASD Annual Meeting
Aroa Biosurgery reports significantly improved healing of diabetic foot ulcers in Symphony trial
Lilly reports positive 48-week Phase 2b resu;ts for EloraTZP
Revvity launches IVDR-certified solution for early detection of type 1 diabetes
Genentech reports positive Phase II results for enicepatide in type 2 diabetes
Bayer's Kerendia wins FDA approval for chronic kidney disease associated with type 1 diabetes
Meant Health announces expansion of telehealth access for FDA-approved GLP-1 prescriptions
Revvity to acquire Human Cell Design to expand metabolic disease drug discovery capabilities
Foventa makes key CMO and CFO appointments
Ascletis Pharma Inc doses first participant in global Phase III clinical programme of ASC30
Daiichi Sankyo data highlight real-world impact of bempedoic acid on cardiovascular risk
Nippon Kinzoku begins mass production of ultra-thin stainless steel for insulin needles
Hanmi Pharm enters exclusive licensing deal with Genentech for obesity therapy HM17321